Neonate with Other Significant Problems DRG Reimbursement

Summary & Overview

Neonate with Other Significant Problems: Inpatient Reimbursement Overview

DRG 794 encompasses neonates with other significant but non-major clinical problems requiring inpatient care; it defines a catchall category for newborns whose conditions do not meet criteria for more specific neonatal Diagnosis-Related Groups. Proper classification into this Diagnosis-Related Group impacts Medicare inpatient reimbursement by grouping similar resource use and determining prospective payment.

Neonate with Other Significant ProblemsDRG Neonate with Other Significant ProblemsDRG 794Diagnosis-Related GroupInpatient ReimbursementMedicareNeonatologyNewborn CareNeonatal MonitoringClinical Coding

DRG 794 Overview

DRG 794 covers neonates with significant clinical problems that do not fit into more specific neonatal Diagnosis-Related Groups, including a range of medical conditions requiring inpatient evaluation, monitoring, or non-complex interventions. This group often includes newborns with conditions such as feeding difficulties, transient metabolic disturbances, or other non-major comorbidities that prolong hospital stay. DRG 794 matters for Medicare payment because it groups resource use for these less complex neonatal cases and influences prospective payment and hospital reimbursement. Accurate clinical coding and documentation determine assignment to this Diagnosis-Related Group and therefore affect payment.

National Payment Rates

Across commercial payers the observed rate range runs from about $370 up to $48K, with means varying by payer (BCBS mean $7.6K, Cigna mean $15K, Anthem mean $15K, Aetna mean $18K). The widest spread between payer minima and maxima is seen in Anthem (min $390 to max $48K). See the table and chart below for payer-level percentiles and distributions.

Mean Rates by Payer — National — DRG 794

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows four columns: average total payment, average submitted covered charges, average Medicare payment amount, and total discharges. These provide a Medicare benchmark for inpatient payments at the national level.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 794 payer rates range from $9.1K to $36K across reported payers, with Cigna at the high end and Blue Cross Blue Shield and Anthem at the low end. This state distribution shows a pronounced divergence where Cigna’s mean is substantially higher than the other local payers. The pattern represents a meaningful deviation from national averages for this DRG; see the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna (mean $36K); Lowest payers: Blue Cross Blue Shield and Anthem (both mean $9.1K).
Alaska’s rates span from $9.1K to $36K, showing a notably higher Cigna mean compared with the much lower state-level means for BCBS and Anthem.
Compared with national patterns, Alaska’s Cigna mean ($36K) is substantially above national medians, while BCBS and Anthem in Alaska sit well below national medians.

Clinical Trials

Trials evaluating acute neonatal stabilization and resuscitation protocols for unstable term and preterm neonates with non-specific but significant problems (eg, respiratory distress not attributable to a single diagnosis, transient metabolic disturbances, or ambiguous sepsis screens). These studies test different monitoring strategies, oxygenation/ventilation approaches, or bundle-based early management algorithms in the first 24–72 hours of life to reduce immediate morbidity and avoid escalation to intensive therapies. Results are directly relevant to clinicians triaging neonates in the DRG and to payers because effective early interventions can shorten length of stay and reduce resource-intensive NICU admissions.
Comparative effectiveness studies of diagnostic and management pathways for neonates with heterogeneous ‘‘other significant problems,’’ such as feeding intolerance, jaundice beyond physiologic limits, mild hypoglycemia, or nonspecific infection workups. These pragmatic studies compare approaches like standardized observation protocols versus more intensive laboratory/imaging workups, or early feeding support versus expectant management, enrolling stable term and late-preterm infants who would otherwise be placed in this DRG. Findings inform evidence-based care algorithms that help hospitals and payers standardize utilization, avoid unnecessary testing, and optimize allocation between regular newborn units and higher-cost NICU beds.
Post-discharge longitudinal outcome and health-services research following neonates classified under this DRG to assess developmental trajectories, readmission rates, and family-centered resource needs. Cohorts include infants discharged after brief neonatal stays for nonspecific but significant problems, with follow-up of neurodevelopmental screening, outpatient visits, and unplanned rehospitalizations over the first 1–2 years. This research is crucial for providers and payers to understand downstream utilization, design targeted post-discharge support or surveillance programs, and to evaluate the cost-effectiveness of early interventions or care pathways implemented during the index admission.

Full Term Neonate with Major Problems: Inpatient Reimbursement Overview

790-EXTREME-IMMATURITY-OR-RESPIRATORY-DISTRESS-SYNDROME-NEONATE

Extreme Immaturity or Respiratory Distress Syndrome, Neonate: Inpatient Reimbursement Overview

789-NEONATES-DIED-OR-TRANSFERRED-TO-ANOTHER-ACUTE-CARE-FACILITY

Neonates, Died or Transferred to Another Acute Care Facility: Inpatient Reimbursement Overview

791-PREMATURITY-WITH-MAJOR-PROBLEMS

Prematurity with Major Problems: Inpatient Reimbursement Overview

792-PREMATURITY-WITHOUT-MAJOR-PROBLEMS

Prematurity without Major Problems: Inpatient Reimbursement Overview

795-NORMAL-NEWBORN

Normal Newborn: Inpatient Reimbursement Overview

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.